Clinical trial · no report yet · Phase 1/Phase 2

HERKULES-3

A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies

NCT05039177 ↗
Completed
Erasca, Inc.
Focused

We haven't built an HCP commentary report on HERKULES-3 (ERAS-007 plus encorafenib plus cetuximab; ERAS-007 plus palbociclib in metastatic colorectal cancer or pancreatic ductal adenocarcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.

Indexed commentary on HERKULES-3 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

Channel	Indexed
X threads	8

Indexed todayTypical once built

The trial

ClinicalTrials.gov

Official title: A Phase 1b/2 Study of Agents Targeting the Mitogen-Activated Protein Kinase Pathway in Patients With Advanced Gastrointestinal Malignancies (HERKULES-3)
Phase: Phase 1/Phase 2
Status: Completed
Conditions: Metastatic Colorectal Cancer; Metastatic Pancreatic Ductal Adenocarcinoma
Interventions: ERAS-007; Encorafenib; Cetuximab; Palbociclib
Arms: Dose Escalation (Parts A1a, A2a, or A3a): ERAS-007 in combination with encorafenib and cetuximab · Experimental
Dose Escalation (Parts B1a, B2a, B3a or B4a): ERAS-007 in combination with palbociclib · Experimental
Dose Expan (Parts A1b, A1c, A2b, A2c, A3b, or A3c): ERAS-007 in combo with encorafenib & cetuximab · Experimental
Dose Expansion (Parts B1b, B2b, B3b, and B4b): ERAS-007 in combination with palbociclib · Experimental
Enrollment: 101
Primary outcomes: Dose Limiting Toxicities (DLT)
Maximum Tolerated Dose (MTD)
Recommended Dose (RD)
Adverse Events
Sponsor: Erasca, Inc.
Start: Sep 20, 2021
Primary completion: Aug 15, 2025
Results posted: No
Registry record: NCT05039177 · updated Mar 25, 2026

Get this report

Focused

Report, built on order: $750

Order this report

Quoted on an estimate of the verified statements in the commentary we've indexed so far. Final coverage is set when we build it.You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded.We build it within 24 hours of confirming your order. If we can't build it to our standard, you aren't charged.

Request a free preview

Ask us to build this report. Once it's built, its free preview (summary, finding titles and coverage) is published on this page and we email you the link. The full report is sold separately. Use your work email; we'll send a link to confirm it.

For agents: .json · .md